表达病毒糖蛋白B、D和I的DNA质粒制剂滴眼免疫对传染性喉气管炎病毒（ILTV）的保护效力
Protection Efficacy of Infectious Laryngotracheitis Virus (ILTV) Immunization by Eye Drop with DNA Plasmid Formulation Expressing Viral Glycoproteins B, D, and I.
文献信息
| PMID | 42937677 |
|---|---|
| 原文 | 在 PubMed 查看原文 ↗ |
| 发表日期 | 2026 |
| 作者 | Roshan Paudel |
| 作者单位 | Department of Population Health, College of Veterinary Medicine, University of Georgia, Athens, GA 30602. |
| 期刊 | Avian diseases |
| SCI 分区 | Q3 |
| IF | 1.8 |
| 研究类型 | 基础研究 · 基础／转化 |
| 所属专科 | 咽喉科 |
中文摘要
尽管针对传染性喉气管炎的减毒活疫苗和重组疫苗已被广泛使用，该病仍对家禽生产构成重大经济挑战。本研究旨在评估表达传染性喉气管炎病毒糖蛋白gB、gD和gI、旨在优先驱动细胞介导免疫应答的DNA质粒混合制剂（PLgBDI）的保护效力。该质粒制剂通过滴眼途径在3日龄和17日龄单独给予无特定病原体鸡，同时也给予此前经胚内免疫过表达gD和gI ILTV抗原的商业rHVT-ND-ILT重组疫苗的鸡。与胚内接种rHVT-ND-ILT重组疫苗不同，滴眼免疫PLgBDI制剂未诱导血清阳转。攻毒后，PLgBDI、rHVT-ND-ILT和rHVT-ND-ILT+PLgBDI免疫组的鸡存活率分别为91%、80%和78%，而NVx/Ch组为65%，在9日龄经滴眼接种鸡胚源（CEO）减毒活疫苗的组为100%。尽管与NVx/Ch组相比无统计学差异，PLgBDI组和rHVT-ND-ILT组呈现临床症状减轻的趋势，而rHVT-ND-ILT+PLgBDI组未观察到该趋势。PLgBDI、rHVT-ND-ILT和rHVT-ND-ILT+PLgBDI免疫组均未显示攻毒病毒复制的减少。总体而言，本研究表明，滴眼免疫DNA质粒混合制剂可诱导与rHVT-ND-ILT相当的部分保护，但当给予此前经胚内接种rHVT-ND-ILT疫苗的鸡时，则削弱了保护作用。
英文摘要
Despite the widespread use of live attenuated and recombinant vaccines against infectious laryngotracheitis, the disease continues to pose substantial economic challenges to poultry production. This study aims to assess the protective efficacy of DNA plasmid pool formulation (PLgBDI) expressing infectious laryngotracheitis virus glycoproteins gB, gD, and gI designed to preferentially drive cell-mediated immune responses. The plasmid formulation was administered to specific-pathogen-free chickens via eye drop at 3 and 17 days of age (doa) by itself, and to chickens previously immunized in ovo with a commercial rHVT-ND-ILT recombinant vaccine that expresses gD and gI ILTV antigens. In contrast to in ovo vaccination with the recombinant rHVT-ND-ILT vaccine, eye drop immunizations with the PLgBDI formulation did not induce seroconversion. Postchallenge, the PLgBDI, rHVT-ND-ILT, and rHVT-ND-ILT+PLgBDI vaccinated groups of chickens exhibited survival rates of 91%, 80%, and 78%, compared to 65% for the NVx/Ch group and 100% for the group vaccinated with the live attenuated chicken embryo origin (CEO) vaccine via eye drop at 9 doa. Although not statistically different to the NVx/Ch group, the PLgBDI and rHVT-ND-ILT groups presented a trend toward reduction in clinical signs that was not observed for the rHVT-ND-ILT+PLgBDI group. Neither the PLgBDI, rHVT-ND-ILT, nor rHVT-ND-ILT+PLgBDI vaccinated groups showed a decrease in challenge virus replication. Overall, this study indicated that eye drop immunization with DNA plasmid pool formulation induced partial protection comparable to that induced by rHVT-ND-ILT, while it deterred protection when administered to previously in ovo rHVT-ND-ILT vaccinated chickens.